Patent Application
20240009205
The present invention concerns the technical field of the pharmaceutical industry.
In particular, the invention relates to a therapeutic combination of a compound having antiestrogenic activity, in particular a compound selected among selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs) and aromatase inhibitors (AIs), and a CDK4/6 inhibitor, for use in the treatment of breast cancer (BC) and other estrogen sensitive cancers in association with and a defined dietetic regimen.
Breast cancer (BC) is the most frequently diagnosed malignancy with 1.7 million new diagnoses/year (23% of cancer diagnoses)1. About 20% of BC recur after curative surgery; moreover, about 10% of all patients present with metastatic breast cancer (mBC) at diagnosis; mBC remains essentially incurable. Approximately 75% of BCs express estrogen receptor (ER) and/or progesterone receptor (PgR). Recently, the introduction of the CDK4/6 inhibitors (CDK4/6inh) palbociclib (PALB), ribociclib or abemaciclib in combination with standard endocrine therapy (ET) has improved progression free survival (PFS) and tumor response rates (RRs) in patients with HR+HER2−mBC2. Despite these improvements, HR+HER2− mBC eventually progresses even under ET+CDK4/6inh [PFS is approximately 24 months in the first-line setting and is about 9 months in endocrine-refractory mBC] and most patients with HR+ mBC still die of their disease.
Therefore, new strategies are needed to enhance the activity of ET, reducing the chances of patient relapse, and to prolong survival and, hopefully, cancer free survival in patients with HR+ mBC.
Periodic cycles of water fasting/fasting mimicking diet (FMD) have antitumor effects in mouse tumor models and synergize with chemotherapy, radiotherapy, and tyrosine kinase inhibitors3. The anticancer properties of fasting/FMD reflect the inability of malignant cells to adapt to rapid nutrient and growth factor deprivation, especially in combination with other therapies.
Moreover, the FMD stimulates tumor infiltration by cytotoxic CD8+ T lymphocytes, while reducing immunosuppressive regulatory T cells. Fasting/FMDs also have the added value of protecting healthy tissues from anticancer treatment-induced toxicity and can induce multisystem pro-regenerative effects4. Clinical studies of fasting/FMD in patients undergoing chemotherapy support its feasibility and safety and, consistent with the mouse data on the effect of fasting/FMDs on chemotherapy tolerability, cycles of FMD were recently reported to help patients maintain their Health Related Quality of Life (HRQoL) and avoid fatigue while receiving chemotherapy for ovarian cancer or BC treatment3,5.
In patent application WO 2017/140641, the present Applicants disclosed a method of treating breast cancer or other estrogen-responsive tumors and cancer in a human patient, wherein the method comprises subjecting the patient to reduced calorie intake for a period of 24-190 hours, while the patient is being treated with a compound having antiestrogenic activity, in particular a SERM, a SERD or an AI.
The Applicants have now surprisingly found that FMD, by virtue of its capability of reducing the circulating growth factors, in particular insulin, Igf-1 and leptin, allows to further increase the progression free survival (PFS) and to induce tumor regressions in mouse models of HR+/HER2− BC when combined with an antiestrogenic compound and with a CDK4/6 inhibitor. In line with these findings in the mouse, very promising results with this approach (combined FMD, antiestrogenic compound and CDK4/6 inhibitors) were obtained in patients enrolled in either one of two clinical trials (NCT03595540, NCT03340935).
In an aspect thereof, the present invention relates to a therapeutic combination of a compound having antiestrogenic activity and a CDK4/6 inhibitor for use in a method for the treatment of breast cancer (BC) or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting said patient to reduced calorie intake for a period of 24-190 hours while said patient is being treated with said therapeutic combination.
The above-mentioned compound having antiestrogenic activity is preferably selected among the group consisting of SERMs, SERDs, and of AIs.
By reduced calorie intake it is hereby meant a daily calorie intake reduced by 10-100%, preferably by 50-100%, more preferably by 75-100%, with respect to the normal calorie intake, including total starvation.
The subject's normal calorie intake is the number of kcal that the subject consumes to maintain his/her weight. The subject's normal calorie intake may be estimated by interviewing the subject or by consideration of a subject's weight. As a rough guide, subject's normal calorie intake is on average 2000-3000 kcal/day for men and 1600-2400 kcal/day for women.
Preferably, when the daily calorie intake is reduced by 10-85%, the patient is fed with foods with a high content of monounsaturated and polyunsaturated fats and a reduced content of proteins and sugars 40% of calories coming from fat). This because a diet based on such foods has beneficial effects that are similar to those of starvation.
Preferably said period of reduced calorie intake ranges from 48 to 150 hours, and most preferably it is of about 120 hours.
Among the SERMs that can be used in the present invention, the following are mentioned: tamoxifen, raloxifene, toremifene, lasofoxifene, ospemifene, arzoxifene, bazedoxifene.
Among the SERDs that can be used in the present invention, the following are mentioned: fulvestrant, RU 58668, GW7604, GDC-0810, AZD9496, pipendoxifene, acolbifene, OP-1074 ((2S)-3-(4-hydroxyphenyl)-4-methyl-2-(4-{2-[(3R)-3-methylpyrrolidin-1-yl]ethoxy}phenyl)-2H-chromen-7-ol).
Fulvestrant is the most preferred SERD for use in the method of the present invention.
Among the AIs that can be used in the present invention, the following are mentioned: anastrozole, exemestane, letrozole, vorozole, formestane, fadrozole.
Among the CDK4/6 inhibitors that can be used in the present invention, the following are mentioned: palbociclib (PALB), ribociclib, aminociclib, abemaciclib, trilaciclib, voruciclib, purvalanol A and olomoucine II. Palbociclib is the most preferred CDK4/6 inhibitor for use in the present method.
In a particular aspect, the present invention relates to a therapeutic combination of fulvestrant and palbociclib for use in a method for the treatment of BC or other estrogen-responsive tumors and cancers in a human patient, wherein the method comprises subjecting said patient to reduced calorie intake for a period of 24-190 hours while said patient is being treated with said therapeutic combination.
As used herein, “cancer” refers to a disease or disorder characterized by uncontrolled division of cells and the ability of these cells to spread, either by direct growth into adjacent tissue through invasion, or by implantation into distant sites by metastasis. The present invention is focused on the treatment of BC, in particular ER-positive BC but it applies to all estrogen-responsive tumors and cancers.
The above-mentioned period of reduced calorie intake with concurrent administration of the compound having antiestrogenic activity to the patient can be repeated one or more times after respective periods of 5-60 days, during which the patient is given the antiestrogenic compound and the CDK4/6 inhibitor while following a diet involving a normal calorie intake.
The above-mentioned reduced calorie intake regimen preferably corresponds to less than 1,200 kcal/day, preferably 300-1,100 Kcal/day.
Such reduced calorie intake can be obtained by means of dietetic foods with reduced calorie, sugar, and protein content, but containing relatively high levels of unsaturated “good fats” and all necessary micronutrients to prevent malnutrition.
In another aspect, the present invention relates to a pharmaceutical composition comprising a compound with antiestrogenic activity as defined above, a CDK4/6 inhibitor as defined above and a pharmaceutically acceptable carrier for use in the method for the treatment of BC and other estrogen-dependent tumors and cancers in a patient as defined above.
As it will become clear from the experimental results reported in the following sections, it has unexpectedly been found that starvation and also a reduced calorie intake for periods of 24-72, positively affect the anticancer efficacy of a concurrent anticancer treatment with a therapeutic combination of compound having antiestrogenic activity and a CDK4/6 inhibitor.
A positive effect on the efficacy of a concurrent anticancer treatment with a therapeutic combination of a compound having antiestrogenic activity and a CDK4/6 inhibitor is also obtained when the above mentioned periods of reduced calorie intake are replaced by corresponding periods of normal calorie intake, during which the patients are only fed with the above-mentioned foods with a high content of monounsaturated and polyunsaturated fats and a reduced content of proteins and sugars (≥40% of calories coming from fat), since a diet based on such foods has beneficial effects that are similar to those of starvation.
In an aspect thereof, the present invention thus also concerns a therapeutic combination of a compound having antiestrogenic activity and a CDK4/6 inhibitor for use in a method for the treatment of cancer in a human patient, wherein the method comprises feeding said patient only with foods with a high content of monounsaturated and polyunsaturated fats and a reduced content of proteins and carbohydrates (≥40% of calories coming from fat), in such an amount as to ensure a normal daily calorie intake, i.e. 2000-3000 kcal/day for an adult male subject and 1600-2400 kcal/day for an adult female subject, for a period of 24-190 hours, while said patients is being treated with said therapeutic combination.
The compounds and compositions according to the invention may be administered with any available and efficient delivery system, comprising, but not limited to, oral, buccal, parenteral, inhalatory routes, topical application, by injection, by transdermic or rectal route (for ex. by means of suppositories) in dosage unit formulations containing conventional, pharmaceutically acceptable and non-toxic carriers, adjuvants and vehicles. The administration by parenteral route comprises subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques.
The solid dosage forms for the administration by oral route comprise, for example, capsules, tablets, powders, granules and gels. In such solid dosage forms, the active compound may be mixed with at least one inert diluent such as, for example, sucrose, lactose or starch. These dosage forms normally also comprise additional substances different from the inert diluents, such as, for example, lubricating agents like magnesium stearate.
The injectable preparations, for example aqueous or oily sterile injectable solutions or suspensions, may be formulated according to the known technique and by optionally using appropriate dispersing, wetting and/or suspending agents.
The pharmaceutical preparations according to the present invention may be produced by using conventional pharmaceutical techniques, as described in the various pharmacopoeias or handbooks of the field such as, for example, “Remington's Pharmaceutical Sciences Handbook”, Mack Publishing, New York, 18th Ed., 1990.
The average daily dosage of the compounds according to the present invention depends on many factors, such as, for example, the seriousness of the disease and the conditions of the patient (age, weight, sex): The dose may generally vary from 1 mg to 1500 mg per day of compound according to the invention, optionally divided into more administrations.
The present invention will be further described with reference to the appended drawings and to certain embodiments, which are provided here below by way of illustration and not of limitation.
Table 1 illustrates results from clinical trials NCT03595540 (pt. #1-24) and NCT03340935 (pt. #25-36).
Table 2 shows the complete blood counts and metabolic panel post FMD in certain patients of the NCT03595540 clinical trial.
Table 3 is a list of primers.
Growth factor signaling through the PI3K/AKT/mammalian target of rapamycin (mTOR) and MAP kinase axes enhances ER activity and is a key mechanism underlying endocrine resistance1,3,7. Water-only fasting (fasting) or plant-based, low-calorie, carbohydrate- and protein-restricted FMDs reduce circulating growth factors, such as insulin and IGF113,7,8. Therefore, the Applicants hypothesized that these dietary interventions could be used to enhance the activity of endocrine therapy (ET) and delay endocrine resistance.
In WO 2017/140641, the present Applicants disclosed that low-serum and low-glucose cell culture conditions designed to mimic the effects of fasting/FMD (STS) increased the antitumor activity of tamoxifen (TMX) or fulvestrant (FULV) in HR+/HER2− BC cell lines, and similar results were obtained in mouse xenografts of the same cell lines with weekly cycles of fasting or FMD.
The enhancement of ET activity through STS was dependent on the reduction in serum, but not in glucose, since adding back the latter to cell growth media did not affect the observed potentiation (
In addition to increasing β-hydroxybutyrate levels (
Thus, the combined effect of these diets was a marked reduction in IGF1 levels and bioavailability. The levels of leptin, an adipokine that acts as a growth factor for HR+ BC cells and reduces ET efficacy11-13, were only reduced when fasting or FMD were combined with ET. Adiponectin, which exerts antitumor effects, was only affected by the combination of fasting and TMX (
To define the role of insulin, leptin, and IGF1 in the FMD-induced potentiation of ET antitumor effects, the Applicants administered each of these factors, which are hereby collectively referred to as Fasting-Reduced Factors (FRFs), to MCF7 xenograft-bearing mice that were being treated with FULV plus FMD (
Adding back any of these factors (or their combination) was sufficient to revert the FMD-induced enhancement of FULV activity (
Withdrawing the FRFs restored tumor sensitivity to ET plus FMD, while administering them to mice that had only received FULV plus FMD stimulated tumor growth and abrogated the FMD-induced potentiation of FULV (
These data are consistent with a previous study demonstrating the key role of insulin reduction in the enhancement of the efficacy of PI3K inhibitors in various cancer types14, but show that the concomitant reduction of additional factors with growth-promoting ability is also important for this therapeutic effect to be achieved. The fact that all these FRFs have overlapping effects in the activation of signaling cascades regulating HR+ BC sensitivity to ET, and in particular the PI3K-AKT-mTOR pathway11,12,14-17, may explain why reducing all three is required to promote ET antitumor activity.
Consistent with this notion, tumors isolated from mice from which FRFs were withdrawn exhibited reduced phosphorylation of AKT and of p70S6K (a mTOR target), while in tumors from animals administered FRFs during treatment with FULV plus FMD, we found levels of AKT and p70S6K phosphorylation that were comparable to those of ad lib. fed mice (
The Applicants monitored the effect of fasting/FMD on additional circulating factors with a reported role in BC pathophysiology17, and found that both fasting and FMD (with or without TMX/FULV) downregulated TNFα, which acts pro-oncogenically by upregulating aromatase in the tumor microenvironment and by enhancing angiogenesis and cell invasion, and IL1β, which enhances HR+ BC cell migration and metastasis17,18 (
Since insulin, IGF1, and leptin down-regulation proved essential for FMD-induced potentiation of ET antitumor activity, the Applicants focused on these FRFs for subsequent mechanistic experiments. However, it is likely that the benefit of fasting/FMD to ET may involve other mediators, such as TNFα and IL1β.
STS and the FMD (in experiments with MCF7 xenografts) cooperated with ET to increase the expression of PTEN, an upstream negative regulator of AKT-mTOR signaling, in HR+ BC cell lines and in HR+/HER2− BC organoids (FIG. 2a-c,
Among the known enhancers of PTEN expression, the Applicants focused on the tumor suppressor EGR1 (whose expression is associated with good prognosis in BC patients19,20) since they previously showed that EGR1 is upregulated in healthy tissues during fasting21 and because EGR1 is suppressed by ER activity22.
EGR1 was increased upon treatment of HR+ BC cell lines and HR+ BC organoids with ET plus STS (
PTEN silencing and expression of a constitutively active AKT [myristoylated (myr)-AKT] also reduced MCF7 sensitivity to combined ET and STS/FMD (
In addition, EGR1 and PTEN upregulation were also abolished by myr-AKT (
This effect was prevented by both PTEN silencing and myr-AKT (
ER activity is essential for HR+ BC cell survival and proliferation, and is enhanced by insulin, IGF1 and leptin signaling at multiple levels1,8,11,16,24. STS reduced ER transcriptional activity and enhanced FULV- and TMX-mediated ER inhibition in HR+ BC cell lines, as indicated by luciferase reporter assays and by the reduction in the expression of the ER target genes TFF1, PGR, and GREBI (
Using gene expression microarrays and Gene Set Enrichment Analysis (GSEA), the Applicants found a downregulation of gene categories belonging to cell cycle-related themes through combined TMX and STS in MCF7 cells (
Consistent with their effects on cell cycle regulators, STS and ET together reduced phosphorylated RB in HR+ BC cells and induced cell cycle arrest in the G0-G1 phase (
Thereafter, the Applicants reasoned that CCND1 downregulation via the combination of ET and STS could be exploited to provide an additional therapeutic effect, by adding a CDK4/6 inhibitor, such as palbociclib (PALB;
However, even with these combinations, resistance acquisition and tumor progression could not be avoided. In contrast, combining FULV, FMD and PALB not only prevented tumor growth for over 160 days, but also led to a slow, but steady, tumor shrinkage. Furthermore, administering FMD cycles to mice with tumors that had already become resistant to FULV plus PALB induced tumor shrinkage even at this advanced stage (
The ability of MCF7 cells from resistant tumors to grow in the presence of FULV and PALB was verified in vitro and in vivo (
The combination of periodic FMD and ET was tested in 36 patients with HR+ BC, who were enrolled in the NCT03595540 (pt. #1-24) and in the NCT03340935 (pt. #25-36) clinical trials.
In the former trial, patients received a previously reported 5-day FMD, every four weeks. They completed on average 6.1 FMD cycles, with some of them receiving up to 13 cycles. Also in this clinical study, the FMD proved to be safe, only leading to G1-2 adverse events, most commonly headache (41%) and fatigue (21%) (Table 1 and 2). Patients from the NCT03340935 21 study received a similar, albeit more calorie-restricted, FMD regimen every 3-4 weeks and completed an average of 5.5 cycles with no severe adverse events (Table 1).
Clinical outcomes in patients with metastatic HR+/HER2− BC, including those treated with combined ET, PALB and FMD (n=4), are promising (
Considering all patients with HR+/HER2− BC enrolled in these trials, the FMD lowered blood glucose, serum IGF1, leptin, and c-peptide, while increasing circulating ketone bodies (
Similar findings were obtained in mice (
Since both leptin and IGF1 stimulate BC cell proliferation11,16,24,29,30, it was evaluated whether these changes in circulating FRFs, which persisted beyond the FMD period, were associated with anticancer effects.
A one-month treatment of MCF7 xenograft-bearing mice with ET plus FMD (or fasting), but not with the single treatments, slowed tumor growth for up to 90 days after treatment withdrawal, and also resulted in enhanced mouse survival (
In addition, mouse pre-treatment with coupled ET and FMD for one 13 month, followed by MCF7 cell inoculation, reduced tumor engraftment and slowed the growth of those tumors that did engraft (
In conclusion, periodic cycles of fasting/FMD increase the anti-cancer activity of TMX and FULV, delay resistance to these agents and, in combination with FULV and PALB, cause tumor regression and reverse acquired resistance to these two drugs.
Pivotal for fasting/FMD-induced enhancement of ET antitumor activity appears to be the simultaneous reduction in blood IGF1, insulin and leptin levels, with the consequent inhibition of the PI3K-AKT-mTOR signalling pathway, at least in part via EGR1 and PTEN upregulation (
Of note, fasting/ FMD provide AKT-mTOR axis inhibition without causing the rebound hyperglycemia and hyperinsulinemia that are instead associated with the use of pharmacologic inhibitors of PI3K or mTORC1, and which were implicated in tumor resistance to these treatment14,31,32.
The leptin- and IGF1-lowering effect of ET plus FMD persists beyond the FMD period and is associated with carryover anticancer activity. Therefore, the observed regression of HR+ BCs in mice could result from the combination of an acute and stronger reduction of FRFs, together with milder, chronic reduction of the same FRFs. In fact, the long-term reduction in leptin and IGF1 may contribute to generate an extended inhospitable environment for HR+ BC cells.
MCF7, ZR-75-1 and T47D cell lines were purchased from ATCC (LGC Standards S.r.l., Milan, Italy). Cells were passaged for less than 6 months before resuscitation for this study. Recombinant human IGF1 and recombinant human leptin were purchased from Peprotech. Insulin (Humulin R) was obtained from the Pharmacy of the IRCCS Ospedale Policlinico San Martino. Puromycin, protease/phosphatase inhibitor cocktail, β-estradiol, sulforhodamine B, TMX and FULV (for in vitro use) were purchased from Sigma Aldrich S.r.l. Fulvestrant for in vivo use was purchased from Astrazeneca (Faslodex). PALB for in vitro experiments was purchased from Selleck Chemicals while for in vivo experiments it was purchased from Medchem Express. 17β-estradiol-releasing pellets were purchased from Innovative Research of America.
2.8×103 MCF7, 5×103 T47D or 5×103 ZR-75-1 cells were plated in 96 well plates in CTR medium. After 24 h medium was removed, cells were washed with PBS and incubated either in CTR (10% FCS and 1 g/L glucose) or STS (1% FBS, 0.5 g/L glucose) medium. After 24 h cells were stimulated w/ or w/o with TMX or FULV at the indicated concentrations. Where indicated, GDC0068, AZD5363 and LY294002 (from SelleckChem) were used at 1 μM, 400 nM and 2 μM concentration, respectively. Viability was determined 72 h later by CellTiter96 Aqueous 1 (Promega) according to the manufacturer's instructions.
Organoid lines used were previously published by Sachs et al. and were cultured and passaged as previously described. For viability assays organoids were collected, washed, filtered with a 70 μm nylon filter (Falcon) and brought to a 7.5×103 organoids/mL density in regular medium or STS 25 medium (0.5 g/L for STS and concentration of B27 brought to 0.1× instead of 1×) containing 5% BME. Thereafter, 40 μL organoid suspension was dispensed in each well of a 384-well plate (Corning) using a Multi-drop Combi Reagent Dispenser (Thermo Scientific). Organoids were subsequently treated with TMX (0.01-55 μM) with 4 replicates for each concentration. TMX was dispensed using the Tecan d300e digital dispenser. DMSO concentrations never exceeded 1%. Five days later, viability was assessed using CellTiterGlow 3D reagent (Promega) according to the manufaturer's instructions. Cell viability was normalized based on the signal obtained in organoids treated with 1 μM staurosporin (Sigma Aldrich; positive control; corresponding to 0% cell viability) and DMSO (negative control, corresponding to 100% viability).
pBABE-puro (PBP), PBP-myr-AKT, pMKO-GFP-shRNA, pMKO-PTEN-shRNA the and lentiviral packaging plasmid (pCMV-dR8.2 dvpr and pCMV-VSV-G) were purchased from Addgene (Cambridge, MA, USA). pLKO and pLKO-EGR1-shRNA1-3 were purchased from Sigma Aldrich S.r.l. Retro- and lentiviral transdution was performed as described elsenwhere34.
For protein lysate generation from cultured cells, 5×104 MCF7, T47D or ZR-75-1 cells were plated in 6-well plates in CTR medium. After 24 h medium was removed, cells were washed with PBS and incubated either in CTR or STS medium. After 24 h cells were stimulated w/ or w/o with TMX (5 μM) or FULV (10 μM). Where indicated, cells were supplemented with insulin (400 μM), IGF1 (5 ng/ml), leptin (50 mg/ml), or 17β-estradiol (100 nM). 24 h later, cells were washed and protein lysates were generated as described elsewhere34,35. Protein lysates from primary tumors or mouse uteri were obtained using TissueRuptor (Quiagen). Proteins (35 μg) were separated by SDS-PAGE, transferred to a PVDF membrane (Immobilon-P, Millipore S.p.A.), and detected with the following antibodies: anti-phospho-AKT (Ser473; #4058), anti-AKT (#9272), anti-PTEN (#9552), anti-phospho-p70S6kinase (Thr389; #9206), anti-p70S6kinase (#9202), anti-4E-BP1 (#4923), anti-phospho-eIF4E (Ser209; #9741), anti-phospho-RB (Ser807/811; #9308), anti-RB (#9309), anti-CCND1 (#2978) were all from Cell Signaling Technology; anti-phospho-AMPK (Thr172; PA5-2 17831), anti-AMPK (PA5-29679), anti-EGR1 (MA5-15008) were from Thermo Fisher; anti-β-actin was from Santa Cruz Biotechnology. Band intensities were quantified by Quantity One SW software (Bio-Rad Laboratories, Inc.) using standard enhanced chemiluminescence.
8×102 MCF7 or 2×103 ZR-75-1 cells were plated in 6-well plates in regular medium. 24 h later cell medium was removed. Cells were washed twice with PBS and were incubated either in CTR or STS medium. The next day cells were treated with either vehicle DMSO, 5 μM TMX or 30 μM fulvestrant for 24 h. Then cell medium was removed and cells were cultured for two weeks. Cell colonies were finally enumerated as described in34.
Cell cycle analysis of cultured BC cells was performed as described elsewhere35.
7.5×103 MCF7, 1×104 T47D or ZR-75-1 cells were plated in 96-well plates in CTR medium. After 24 h the cell medium was removed, cells were washed with PBS and then incubated either in CTR or STS medium. 24 h later cells were stimulated w/ or w/o TMX (5 μM) or FULV (10 μM). Protein synthesis was determined with Click-iT™ Plus OPP Alexa Fluor™ 488 Protein Synthesis Assay Kit (Life Technologies) with PerkinElmer Operetta® High Content Imaging System.
For ER luciferase reporter assays, 4×104 MCF7 cells were seeded in a 24-well plate 48 h before transfection. Cells were grown in phenol red free regular medium, supplemented with 10% charcoal stripped FBS (Gibco). Cell medium was then replaced and substituted with either regular or STS phenol red free medium, containing 10% or 1% charcoal treated FBS respectively, and 70% confluent cells were transfected with TransIT®-LT1 Transfection Reagent (Mirus). 350 ng of pGL3 promoter plasmid (Promega) or of the pS2/TFF1 reporter vector containing 1.3 kb of the proximal promoter of the estrogen-responsive gene TFF1 cloned in the pGL3-basic backbone36 were used together with 150 ng of the pRLSV40 plasmid (Promega), which harbours the luciferase gene from Renilla reniformis under a constitutive promoter. The next day, transfected cells were treated w/ or w/o TMX (5 μM), FULV (10 μM), 17β-estradiol (1 nM) and harvested after additional 24 h. Luciferase signals were measured using the Dual-Luciferase® Reporter Assay System (Promega) as 9 described previously36.
For gene expression microarray studies of cultured MCF7 cells, 5×104 cells were plated in 6-well plates in CTR medium. After 24 h medium was removed, cells were washed with PBS and incubated either in CTR or STS medium. After 24 h, cells were stimulated w/ or w/o with 5 μM TMX. 24 h later, total RNA isolation was performed with the RNeasy Mini Kit (Quiagen, GmbH Hilden, Germany). RNAs were hybridized in quadruplicate on Agilent Human GE 4x44K V2 Microarray (G2519F-026652) following the manufacturer's protocol. Hybridized microarray slides were scanned with the Agilent DNA Microarray Scanner G2505C at a 5 μm resolution with the manufacturer's software (Agilent ScanControl 8.1.3). The scanned TIFF images were analysed numerically and background-corrected using the Agilent Feature Extraction Software (version 21 10.7.7.1), according to the Agilent GE1_107_Sep09 standard protocol. The output of Feature Extraction was analysed with the R software environment for statistical computing (http://www.r-project.org/) and the Bioconductor packages (http://www.bioconductor.org/). The arrayQuality Metrics package was used to check the quality of the arrays. Low signal Agilent probes, identified by a repeated “not detected” flag across the majority of the arrays in every condition, were filtered out from the analysis. Signal intensities across arrays were background corrected (Edwards method) and normalized with the quantile normalization method. DEGs were determined adopting a double threshold based on 1) the magnitude of the change (fold change greater than ±2) the statistical significance of the change, measured with multiple-test-correction adjusted p-value (q-value), less than 0.05, using Limma package. Gene set enrichment analysis was performed using the version implemented in fgsea package, performing 10000 permutations and using as database the REACTOME Pathways dataset (reactome.db package). Box-plots were generated using ggplot2 package and to evaluate the differences between the groups, non-parametric Wilcoxon-test was used.
QPCR were performed as described elsewhere35. Gene-specific primers were purchased from Sigma-Aldrich or Thermo Fisher and are listed in Table 3. Comparisons in gene expression were performed using the 2-ΔΔCt method.
Mice whole blood was collected in Eppendorf. It was allowed to coagulate for 2 h at RT, centrifuged 20 minutes at 4,000 rpm, then aliquoted into PCR tubes and stored at −80° C. until subsequent use. Patients whole blood was collected in Vacuette Serum Clot Tubes, centrifuged 20 minutes at 2,100 rpm then aliquoted into small tubes and stored at −80° C. until use. All the ELISAs assay to detect murine and human serum level of IGF-1, IGFBP1, IGFBP3, c-peptide, leptin and adiponectin were purchased from R&D System except for murine c-peptide which was purchased from Alpco.
All mouse experiments were performed in accordance with the relevant laws and institutional guidelines for animal care and use established in the Principles of Laboratory Animal Care (directive 86/609/EEC), upon approval by the Italian Istituto Superiore di Sanità. NOD SCID-γ mice were utilized in the experiments from
To allow MCF7, T47D and ZR-75-1 xenografts growth, the day before cell injection a 17β-estradiol-releasing pellet (Innovative Research of America) was inserted in the intra-scapular subcutaneous region under anesthesia conditions. 5×106 MCF7, 8×106 ZR-75-1, or 5×106 T47D cells were injected s.c. to either one or both flanks of the mouse. Alternatively, 2.5×106 MCF7 were injected orthotopically into the fourth abdominal fat pad (experiments from
The NCT03595540 was conducted at the IRCCS Ospedale Policlinico San Martino. This trial consists of a single-arm phase II clinical study of a FMD (Prolon, by L-Nutra, Los Angeles, CA) in 60 patients with solid or hematologic tumors undergoing active cancer treatment. It is aimed at assessing feasibility, safety and effects on patient nutritional status of a FMD in patients with different cancer types and concomitant anticancer treatment. An amendment to the protocol (which includes the possibility of using imaging studies that are otherwise routinetly prescribed for disease monitoring, e.g. CT scans, for body composition evaluation) was approved by the Ethics Committee of the Regione Liguria on Apr. 8, 2019 (#27). The FMD tested was described elesenwhere4,6. Throughout the clinical study, patients have received dietary counseling for the intervals between FMD cycles, aiming at providing an appropriate intake of proteins (1.5 g/kg ideal weight/day, primarily from seafood and legumes), essential fatty acids, vitamins and minerals25,26 and have also been invited to perform light/moderate daily muscle training (e.g. 500-600 kJ/day; as allowed by their medical condition; https://docs.google.com/presentation/d/1szaRW4t-pZQI17o2Pe0747FsUEOVWWiA6BHja0p8H_0/edit#slide=id.g34ad7971 84_0_0) to enhance muscle anabolism48. Between FMD cycles patients were prescribed amino acid supplements 11 (Aminotrofic; 30 g essential amino acids two times a day) in the presence of a difficulty in maintaining phase angle values of 5 degrees or greater. Additional information on this trial is available at: https://clinicaltrials.gov/ct2/show/NCT03595540. Patient serum for subsequent ELISA assays of circulating growth factors and adipokines has been routinely collected before commencement of the first and of the second FMD cycle. In addition, in those patients who live close to the enrolment site, blood draws were also performed on day 6 of the FMD at cycle. Blood glucose and ketone bodies were self-measured by the patients using Glucomen Areo 2k (Menarini).
The NCT03340935 clinical trial, was conducted at the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. This study is aimed at assessing the safety, feasibility and metabolic effects of a FMD in cancer patients treated with different standard antitumor therapies. Patients with any malignancy, with the exception of small cell neuroendocrine tumors, were considered for enrollment in this study. The FMD was administered up to a maximum of 8 consecutive cycles in combination with standard adjuvant treatments or therapies for advanced disease. The FMD utilized in this study consisted of a 5-day plant-based, low-calorie (600 Kcal on day 1, followed by 300 KCal/day on days 2 to 5), low-protein, low carbohydrate diet (patent pending). The FMD was repeated every 3 or 4 weeks up to a maximum of 8 consecutive cycles. Additional information on this trial can be obtained at: https://clinicaltrials.gov/ct2/show/NCT03340935. 2
CT scans of Pt. #1 and Pt. #3 were acquired with different CT scanners. Both 1.25-mm and 5-mm slice thickness with standard body kernel were available. The whole body was scanned from the lung apex to the pubic symphysis (Pt. #1). Reconstructed axial images with both a 1.25-mm and a 5-7 mm slice thickness were analysed using the software installed on the workstations of the IRCCS Ospedale Policlinico San Martino Radiology Department (Suite-Estensa 1.9-Ebit-Esaote Group Company, 2015). The third lumbar vertebra (L3), at the level in which both transverse processes are clearly visible, was the bony landmark for the estimation of total muscle area and subcutaneous fat. If abdominal CT scans were not available, but only thoracic CT was present (Pt. #3), estimation of total muscle area (red areas) and fat at the level of the Louis angle (manubriosternal joint that lies at the level of the second costal cartilage) at baseline and after repeated FMD cycles were done according to49.
All in vitro data are represented as mean±SD of at least three independent experiments. All in vivo data are represented as mean±SEM. Statistical analyses were performed with GraphPad Prism software version 5 (GraphPad Software). All parameters were tested by paired t test or one-way ANOVA followed by Tukey's test. p values<0.05 were considered significant. To evaluate changes in fat-free body mass, fat body mass and phase angle over time, a linear mixed effects model was fitted taking into account absolute (values expressed as kgs) fat-free body mass, absolute fat body mass (values expressed as kgs) and phase angle (values expressed as degrees) as a function of time assessment, with a random covariate represented by subject ID (package lme4 in the R Environment for Statistical Computation). The following abbreviations were utilized in our figure legends to 1 define the degree of significance: ns: non-significant; *: p<0.05; **: p<0.01; ***: p<0.001.
| Number | Date | Country | Kind |
|---|---|---|---|
| 102020000008710 | Apr 2020 | IT | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2021/060341 | 4/21/2021 | WO |
